title: Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose.
abstract: Oritavancin is a novel glycopeptide currently being developed for the treatment of complicated skin and skin structure infections (cSSSI), including those caused by multidrug resistant gram-positive pathogens. The disposition of oritavancin in skin structures was investigated using a cantharide-induced blister fluid model. Seventeen healthy male subjects received oritavancin, but only 16 subjects were evaluated after one subject discontinued study drug. Each subject (eight per dose group) received 200 mg of oritavancin once a day for 3 days (group A) or 800 mg as one single dose (group B). Group A plasma samples and exudates from blister fluid were collected on days 3, 4, 7, 9, and 12 and on days 3, 4, 7, and 9, respectively. Group B samples and exudates were collected on days 1, 2, 5, 7, and 10 and on days 1, 2, 5, and 7, respectively. Drug concentrations were determined using a liquid chromatography-tandem mass spectrometry assay and, subsequently, pharmacokinetic analysis was performed. Differences between treatment groups in ratios for area under the concentration-time curve for blister fluid and plasma (AUC(blister fluid)/AUC(plasma) ratios) were evaluated using a t test (alpha = 0.05). Mean maximum concentration of drug in plasma or blister fluid was approximately 8-fold and 11-fold higher in plasma than in blister fluid following the 200- or 800-mg doses of oritavancin, respectively. Mean AUC(blister fluid)/AUC(plasma) ratios at 24 h were 0.190 (standard deviation [SD], 0.052) and 0.182 (SD, 0.062) for groups A and B, respectively (P = 0.791). To place these results in a clinical context, mean drug concentrations in blister fluid exceed the oritavancin MIC at which 90% of strains are inhibited of Staphylococcus aureus (2 microg/ml) by approximately 2- to 5.5-fold at 12 h and 1.5- to 3-fold at 24 h following administration of both dosing regimens. These results support the potential use of oritavancin for the treatment of cSSSI.
authors.affiliation: Cognigen Corporation, 395 Youngs Rd., Buffalo, NY 14221-5831, USA. gerald.fetterly@cognigencorp.com
authors.forename: Gerald J
authors.initials: GJ
authors.lastname: Fetterly
authors.forename: Christine M
authors.initials: CM
authors.lastname: Ong
authors.forename: Sujata M
authors.initials: SM
authors.lastname: Bhavnani
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Loutit
authors.forename: Steven B
authors.initials: SB
authors.lastname: Porter
authors.forename: Lisa G
authors.initials: LG
authors.lastname: Morello
authors.forename: Paul G
authors.initials: PG
authors.lastname: Ambrose
authors.forename: David P
authors.initials: DP
authors.lastname: Nicolau
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001768:Blister / Q000188:drug therapy / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D006020:Glycopeptides; D006801:Humans; D000077427:Lipoglycopeptides; D008297:Male; D008875:Middle Aged; D010949:Plasma / Q000378:metabolism*; D012867:Skin; D012869:Skin Absorption; D017192:Skin Diseases, Bacterial / Q000188:drug therapy / Q000378:metabolism; D014640:Vancomycin / Q000031:analogs & derivatives
chemical_list: D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; C100708:oritavancin; D014640:Vancomycin